John Calfee was a resident scholar at the American Enterprise Institute who specialized in pharmaceutical economics, health policy, and regulatory issues. He contributed articles to The Weekly Standard analyzing tobacco regulation, drug pricing, and patient autonomy in healthcare. His work drew on extensive expertise in the economics of the FDA and health markets.
THOUSANDS OF MULTIPLE SCLEROSIS (MS) patients got an all-too-familiar message recently: Their lives are ruled by experts. The issue was their access to Tysabri, a breakthrough biotech drug with a unique ability to slow down the debilitating progression so feared by MS patients. The manufacturers…
A VOTE IS IMMINENT in the House of Representatives on whether to vastly expand the importation of prescription drugs from a long list of nations including Canada, all of the European Union, Eastern European nations to be admitted to the E.U. in 2004, Israel, and South Africa. The House vote is an…
The war on tobacco has turned upside down. For decades, as new information emerged about the health effects of smoking, public policy relentlessly emphasized individual decision-making. This brought real achievements -- notably, a 40 percent reduction in U.S. per capita cigarette consumption…